Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 3.13% |
| 2 | Technology | 2.97% |
| 3 | Financials | 2.19% |
| 4 | Consumer Discretionary | 2.09% |
| 5 | Industrials | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
13001
CALL
Milestone Scientific
MLSS
$43.9M
| $24.5K | ﹤0.01% |
25,500
-36,700
| -59% | -$30.3K |
|
|
YRD
13002
CALL
Yiren Digital
YRD
$104M
| $24.5K | ﹤0.01% |
5,100
+1,600
| +46% | +$8.93K |
|
|
MURA
13003
PUT
DELISTED
Mural Oncology
MURA
| $24.5K | ﹤0.01% |
+7,600
| New | +$26.8K |
|
|
TBHC
13004
PUT
DELISTED
The Brand House Collective
TBHC
| $24.5K | ﹤0.01% |
15,100
+2,500
| +20% | +$4.52K |
|
|
VBTX
13005
PUT
DELISTED
Veritex Holdings
VBTX
| $24.4K | ﹤0.01% |
900
-200
| -18% | -$5.64K |
|
13006
CALL
Orion Energy Systems
OESX
$79.1M
| $24.4K | ﹤0.01% |
3,050
+350
| +13% | +$3.07K |
|
|
DRRX
13007
DELISTED
DURECT Corp
DRRX
| $24.4K | ﹤0.01% |
32,484
-42,179
| -56% | -$47.1K |
|
13008
Psyence Biomedical
PBM
$13.3M
| $24.2K | ﹤0.01% |
231
+186
| +413% | +$44.3K |
|
13009
CALL
Santander
BSBR
$43.2B
| $24.2K | ﹤0.01% |
6,200
-4,300
| -41% | -$19.7K |
|
13010
PUT
RF Industries
RFIL
$148M
| $24.2K | ﹤0.01% |
6,200
-5,400
| -47% | -$21.8K |
|
13011
PUT
Star Group
SGU
$415M
| $24.2K | ﹤0.01% |
2,100
-800
| -28% | -$9.41K |
|
13012
PUT
Relmada Therapeutics
RLMD
$512M
| $24.2K | ﹤0.01% |
46,500
-4,100
| -8% | -$10K |
|
|
LUXH
13013
DELISTED
LuxUrban Hotels Inc. Common Stock
LUXH
| $24.2K | ﹤0.01% |
25,778
+18,001
| +231% | +$45K |
|
13014
PUT
inTEST
INTT
$179M
| $24.1K | ﹤0.01% |
2,800
-20,400
| -88% | -$154K |
|
13015
ABVC BioPharma
ABVC
$24M
| $24K | ﹤0.01% |
+40,743
| New | +$22.7K |
|
|
LUCK
13016
CALL
Lucky Strike Entertainment
LUCK
$949M
| $24K | ﹤0.01% |
2,400
+800
| +50% | +$9.17K |
|
13017
CALL
Matrix Service
MTRX
$335M
| $23.9K | ﹤0.01% |
2,000
-2,100
| -51% | -$25.7K |
|
|
BLDP
13018
CALL
Ballard Power Systems
BLDP
$814M
| $23.9K | ﹤0.01% |
14,400
+1,200
| +9% | +$1.87K |
|
13019
CALL
ICF International
ICFI
$1.59B
| $23.8K | ﹤0.01% |
200
-200
| -50% | -$29.9K |
|
13020
PUT
Towne Bank
TOWN
$3.5B
| $23.8K | ﹤0.01% |
700
+600
| +600% | +$20.9K |
|
|
OKYO
13021
OKYO Pharma
OKYO
$79.8M
| $23.8K | ﹤0.01% |
20,729
+5,853
| +39% | +$6.28K |
|
13022
PUT
Expensify
EXFY
$210M
| $23.8K | ﹤0.01% |
7,100
| – | – |
|
13023
PUT
Veracyte
VCYT
$3.32B
| $23.8K | ﹤0.01% |
600
-100
| -14% | -$3.79K |
|
|
AMRN
13024
PUT
Amarin Corp
AMRN
$297M
| $23.7K | ﹤0.01% |
2,440
-570
| -19% | -$6.1K |
|
13025
CALL
US Global Investors
GROW
$39.4M
| $23.7K | ﹤0.01% |
9,700
-6,400
| -40% | -$15.7K |
|
Similar funds
Citadel Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Citadel Advisors held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Citadel Advisors deployed $35.2B of net new capital in Q4 2024, opening 1,745 new positions and adding to 6,428 existing holdings. Its largest new stake was Zoetis: 1,090,499 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 3.1% of assets, up from 2.9% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B trimmed.
- Citadel Advisors's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Citadel Advisors added most to Boeing in Q4 2024, an estimated $830M increase.
- Citadel Advisors's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Citadel Advisors fully exited Spotify in Q4 2024, selling an estimated $473M.
- Citadel Advisors's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Citadel Advisors opened 1,745 new positions and closed 1,423 in Q4 2024.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.